Age: 66.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: Blood pressure decreased, Blood pressure measurement, Fatigue, Herpes zoster, Syncope
Clinical narrative: He also ended up getting shingles because it lowered his resistance; Knocked him down for over a month; Blood pressure dropped; Collapsed after taking the shot; This spontaneous case was reported by a consumer and describes the occurrence of HERPES ZOSTER (He also ended up getting shingles because it lowered his resistance) and SYNCOPE (Collapsed after taking the shot) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product RELUGOLIX (ORGOVYX) tablet for Malignant neoplasm of prostate.    Concurrent medical conditions included Prostate cancer NOS.   On 03-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient started RELUGOLIX (ORGOVYX) (Oral) 120 milligram once a day. On 05-Nov-2021, the patient experienced BLOOD PRESSURE DECREASED (Blood pressure dropped) and SYNCOPE (Collapsed after taking the shot) (seriousness criterion medically significant). On an unknown date, the patient experienced HERPES ZOSTER (He also ended up getting shingles because it lowered his resistance) (seriousness criterion medically significant) and FATIGUE (Knocked him down for over a month). At the time of the report, HERPES ZOSTER (He also ended up getting shingles because it lowered his resistance), BLOOD PRESSURE DECREASED (Blood pressure dropped), SYNCOPE (Collapsed after taking the shot) and FATIGUE (Knocked him down for over a month) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 05-Nov-2021, Blood pressure measurement: dropped (Inconclusive) dropped.         Concomitant product use was not provided by the reporter.  The patient received Orgovyx, 120 milligrams daily via oral route on an unknown date (on 02-Nov-2021 with Biologics) for malignant neoplasm of prostate.  Treatment information was not provided. Company Comment: This is a spontaneous case, received by another Pharmaceutical Company,  concerning a 66-year-old, male patient with a history of Prostate cancer under ongoing treatment, who experienced the serious events of syncope and herpes zoster. The event syncope occurred 2 days after receiving the 3rd dose of mRNA1273, however it is unknown the latency of event Herpes Zoster. No information about primary vaccination was provided. Orgovyx (relugolix) is also considered a suspect drug as patient recently started treatment, on a unknown date, with this drug, for Prostate Cancer. Despite the strong temporal association of the event syncope and the vaccine, Orgovyx is a confounder as fatigue and anemia are common adverse drug reactions. Assessed the events as not related to their drug. The benefit-risk relationship of mRNA-1273 in not affected by this report.; Sender's Comments: This is a spontaneous case, received by another Pharmaceutical Company,  concerning a 66-year-old, male patient with a history of Prostate cancer under ongoing treatment, who experienced the serious events of syncope and herpes zoster. The event syncope occurred 2 days after receiving the 3rd dose of mRNA1273, however it is unknown the latency of event Herpes Zoster. No information about primary vaccination was provided. Orgovyx (relugolix) is also considered a suspect drug as patient recently started treatment, on a unknown date, with this drug, for Prostate Cancer. Despite the strong temporal association of the event syncope and the vaccine, Orgovyx is a confounder as fatigue and anemia are common adverse drug reactions. Assessed the events as not related to their drug. The benefit-risk relationship of mRNA-1273 in not affected by this report.